Publications by authors named "Xing-Hui Liao"
We report a case of concomitant EML4-ALK and TPM3-ROS1 fusion in non-small cell lung cancer (NSCLC) in a 47-year-old Chinese man and review the clinical characteristics of this type double of fusion. The patient presented with a local tumor of the left upper lobe and underwent thoracoscopy. Postoperative surgical pathologic staging revealed T N M stage IA.
View Article and Find Full Text PDFROS1 rearrangement occurs in 1-2% of non-small cell lung cancer (NSCLC) cases. These patients would benefit from treatment with the anaplastic lymphoma kinase inhibitor, crizotinib; however, resistance to crizotinib inevitably develops in such patients despite an initial response. The mechanism of acquired resistance to crizotinib in patients with NSCLC with ROS1 rearrangement has not yet been identified.
View Article and Find Full Text PDFArticle Synopsis
- Anaplastic lymphoma kinase (ALK) rearrangement in lung cancer typically responds to ALK tyrosine kinase inhibitors (TKIs) like crizotinib, but many patients eventually develop resistance.
- The case of a 49-year-old man with adenocarcinoma illustrates this, as he transformed to small-cell lung cancer after initially being treated successfully with crizotinib.
- Advanced genomic testing revealed a new mutation in the ALK gene and a rearrangement, indicating that the tumor could have been heterogeneous from the start or evolved during treatment.